Last Year’s Agenda
A preliminary agenda will be announced in Fall 2020.
Monday, November 18
12:30 – 1:00 PM
Registration and Lunch
Welcome and Opening Remarks
Amy Comstock Rick, President & CEO, Food and Drug Law Institute (FDLI)
The federal regulatory climate regarding cannabis-derived products is currently in a state of flux. This session will discuss the current status of cannabis regulation among various federal agencies, including the Drug Enforcement Administration (DEA), the United States Department of Agriculture (USDA), the Environmental Protection Agency (EPA), the U.S. Department of Justice (DOJ), and the Federal Trade Commission (FTC). The panelists will also explore how the Agriculture Improvement Act of 2018 (Farm Act) changed the federal regulation of hemp-containing products such as CBD, and the interplay between the Farm Act’s lack of federal preemption and state laws.
Larry K. Houck, Attorney, Hyman, Phelps & McNamara, PC
Keith Matthews, Of Counsel, Wiley Rein LLP
Kristi L. Wolff, Partner, Kelley Drye & Warren LLP
Moderated by William A. Garvin, Shareholder, Buchanan Ingersoll & Rooney PC
Coffee and Networking Break
Since passage of the Farm Act, what is the legal status of CBD-containing products and accessories sold as drugs, devices, foods, dietary supplements, vaping products, and/or cosmetics under the Federal Food, Drug, and Cosmetic Act (FD&C Act)? Are there solutions to the legal inconsistencies under the current statutory structure? Do recent FDA enforcement actions give us a glimpse into the future?
Brian J. Malkin, Counsel, Arent Fox LLP
Frederick A. Stearns, Partner, Keller and Heckman LLP
Christopher Van Gundy, Partner, Sheppard Mullin Richter & Hampton LLP
Moderated by Elizabeth Oestreich, Vice President, Regulatory Compliance, Greenleaf Health, Inc.
The US is currently a patchwork of state laws and regulations pertaining to medical and adult-use marijuana. State requirements for hemp-derived products also vary widely due to the Farm Act’s lack of preemption. This panel will address the current status of state regulation, whether the Farm Act changes the state landscape, state-level social equity initiatives, and lessons learned from Colorado’s experience with marijuana legalization.
Jonathan A. Havens, Partner, Saul Ewing Arnstein & Lehr LLP
Steven N. Levine, Partner, Husch Blackwell LLP
Sharon Mayl, Senior Advisor for Policy, Office of Food Policy and Response, FDA
Introduced by Melissa S. Scales, Assistant Director, Educational Programs, FDLI
Sponsored by Arnold & Porter
Tuesday, November 19
8:30 – 8:55 PM
Registration and Continental Breakfast
8:55– 9:00 AM
Welcome and Announcements
Laura Brown, Director, Educational Programs, FDLI
Although the Farm Act has removed some barriers for hemp-derived products, many legal and practical issues during the implementation phase remain. This panel will address how USDA’s implementing regulations are likely to affect cultivation and sale of hemp-containing products such as CBD, and issues resulting from the residual state legalization patchwork of hemp products despite passage of the Federal Farm Act.
Mai T. Dinh, Assistant General Counsel, Marketing, Regulatory, and Food Safety Programs Division, Office of the General Counsel, U.S. Department of Agriculture
Patrick Moen, Managing Director and General Counsel, Privateer Holdings
Evelina Norwinski, Partner, Arnold & Porter LLP
Moderated by Rick R. Ball, Partner, Duane Morris LLP and Treasurer, FDLI Board of Directors
Coffee and Networking Break
The DEA has traditionally restricted U.S. research on cannabis-derived products to plants grown at the University of Mississippi. How did the Farm Act change the scope of this research? In the midst of increased demand for research on potential therapeutic outcomes, what is the current status of DEA’s review of other potential research facilities? This panel will also provide an overview of the current state of cannabis research regarding both therapeutic benefits and acute and long-term toxicity. Speakers will explore current restrictions on research, including access issues, and how GW Labs was able to conduct the research necessary to obtain FDA approval of Epidiolex.
Aidan Hampson, Special Content Expert Cannabis, National Institute on Drug Abuse, National Institutes of Health
Angelique Lee-Rowley, Global Chief Compliance Officer, Greenwich Biosciences
Heike Newman, Senior Regulatory Manager, University of Colorado
Moderated by Christina M. Markus, Partner, King & Spalding
This session will address safety and quality of CBD and other cannabis-derived products in this era of scant federal regulation. Speakers will discuss practical issues involving toxicology and cGMPS, analytical testing, pesticide use, and verifying consistent and stable dosages amid varying mixtures of ingredients. Speakers will discuss whether FDA’s existing authority regarding safety and quality covers these products and where gaps exist. The panel will also discuss potential impacts to the cannabis industry from recent vaping lung illnesses.
Deborah Miran, Former Commissioner, Maryland Medical Cannabis Commission
Jessica Parsons O’Connell, Partner, Covington & Burling LLP
Lee Rosebush, Partner, BakerHostetler
Moderated by Libby Baney, Partner and Co-Leader – Health and Life Sciences Industry Team, Faegre Baker Daniels
What do manufacturers need to know about federal regulation of CBD labeling and marketing? We will cover issues such as directions for use, warnings, certificates of analysis, and finding industry-wide consistency in product labeling terms. We will also discuss the fine line between structure-function and disease claims, advertising and promotion issues, and areas where FDA and FTC have stepped in to enforce. Finally, we will discuss ways to minimize risk when labeling and advertising cannabis-derived products.
Richard Cleland, Assistant Director, Bureau of Consumer Protection, Division of Advertising Practices, Federal Trade Commission
Areta L. Kupchyk, Partner, Foley Hoag LLP
Douglas MacKay, Senior Vice President, Scientific and Regulatory Affairs, CV Sciences
Moderated by Stuart M. Pape, FDA Practice Chair, Polsinelli PC
Regulatory updates regarding cannabis-derived products are happening quickly, making it difficult for businesses to predict what’s ahead. Is the CBD market likely to continue its explosive growth? Will increased research lead to more FDA-approved THC- and CBD-containing drugs? Will legalization of state medical/adult-use marijuana continue to spread? With more than half of Americans supporting marijuana legalization in some form, how probable is federal legalization? What would marijuana legalization at the federal level look like? Is Congress likely to enact banking protections for cannabis businesses? This session will discuss the future of federal and state regulation. We will also cover whether legalization in other countries, such as Canada, is likely to impact U.S. policies.
Linda D. Bentley, Member, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Kelly Fair, Director of Legal, USA, Canopy Growth Corporation
Andrew Kline, Director of Public Policy, National Cannabis Industry Association
Moderated by Michael Werner, Partner, Holland & Knight LLP
Closing Remarks and Adjournment